Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Consolidation for ovarian cancer in remission.

× No keyword cloud information.

9 in total

Review 1. Clinical radioimmunotherapy--the role of radiobiology.

Authors: Jean-Pierre Pouget; Isabelle Navarro-Teulon; Manuel Bardiès; Nicolas Chouin; Guillaume Cartron; André Pèlegrin; David Azria
Journal: Nat Rev Clin Oncol Date: 2011-11-08 Impact factor: 66.675

2. Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Authors: Michelle L Harrison; Martin E Gore; David Spriggs; Stan Kaye; Alexia Iasonos; Martee Hensley; Carol Aghajanian; Ennapadam Venkatraman; Paul Sabbatini
Journal: Gynecol Oncol Date: 2007-07-05 Impact factor: 5.482

3. Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.

Authors: Alexia Iasonos; Paul Sabbatini; David R Spriggs; Carol A Aghajanian; Roisin E O'Cearbhaill; Martee L Hensley; Howard T Thaler
Journal: Int J Gynecol Cancer Date: 2012-01 Impact factor: 3.437

Review 4. Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Authors: Rachel N Grisham; Jonathan Berek; Jacobus Pfisterer; Paul Sabbatini
Journal: Immunotherapy Date: 2011-02 Impact factor: 4.196

5. Progranulin is a potential prognostic biomarker in advanced epithelial ovarian cancers.

Authors: Jasmine J Han; Minshu Yu; Nicole Houston; Seth M Steinberg; Elise C Kohn
Journal: Gynecol Oncol Date: 2010-10-15 Impact factor: 5.482

6. Consolidation strategies in ovarian cancer: observations for future clinical trials.

Authors: Paul Sabbatini; David Spriggs; Carol Aghajanian; Martee Hensley; William Tew; Jason Konner; Kathryn Bell-McGuinn; Margrit Juretzka; Alexia Iasonos
Journal: Gynecol Oncol Date: 2010-01 Impact factor: 5.482

7. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.

Authors: Roisin E O'Cearbhaill; Wei Deng; Lee-May Chen; Joseph A Lucci; Kian Behbakht; Nick M Spirtos; Carolyn Y Muller; Benedict B Benigno; Matthew A Powell; Emily Berry; Krishnansu S Tewari; Parviz Hanjani; Heather A Lankes; Carol Aghajanian; Paul J Sabbatini
Journal: Gynecol Oncol Date: 2019-10-22 Impact factor: 5.482

8. Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin?

Authors: Hee Seung Kim; Noh-Hyun Park; Hyun Hoon Chung; Jae Weon Kim; Yong-Sang Song; Soon-Beom Kang
Journal: Jpn J Clin Oncol Date: 2008-05-27 Impact factor: 3.019

9. A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

Authors: Roisin E O'Cearbhaill; Govind Ragupathi; Jianglong Zhu; Qian Wan; Svetlana Mironov; Guangbin Yang; Maria K Spassova; Alexia Iasonos; Sara Kravetz; Ouathek Ouerfelli; David R Spriggs; Samuel J Danishefsky; Paul J Sabbatini
Journal: Cancers (Basel) Date: 2016-04-22 Impact factor: 6.639

9 in total